Study guide
6.4 Bleeding Disorders & Anticoagulation
MFDS Part 1 Membership of the Faculty of Dental Surgery
Track your progress as you read
Finished sections get a check mark.
1 Introduction & Exam Overview
Current Exam Facts How to Use This Guide Eligibility, Booking & the MFDS Pathway
2 Basic Sciences, History Taking & Clinical Assessment
1.1 Head & Neck Anatomy and Underpinning Basic Sciences 1.2 History Taking, Communication & Clinical Examination 1.3 Special Tests, Investigations & Diagnostic Accuracy 1.4 Differential Diagnosis, Triage & When to Biopsy 1.5 Dental Anomalies & Developmental Conditions
3 Cariology, Operative Dentistry & Endodontics
2.1 Cariology & Caries Diagnosis 2.2 Caries Management & Prevention 2.3 Operative Dentistry & Cavity Preparation 2.4 Endodontics 2.5 Tooth Surface Loss & Tooth Discolouration
4 Periodontology & Prosthodontics
3.1 Periodontology 3.2 Fixed Prosthodontics 3.3 Removable Prosthodontics 3.4 Occlusion & Occlusal Assessment
5 Paediatric Dentistry, Orthodontics & Dental Trauma
4.1 Paediatric Dentistry 4.2 Orthodontics 4.3 Dental Trauma 4.4 Orthodontic Assessment, Indices & Referral 4.5 Impacted Teeth & Radiographic Localisation
6 Oral Surgery, Treatment Planning & Prevention
5.1 Oral Surgery & Extractions 5.2 Treatment Planning & Patient Management 5.3 Prevention & Health Promotion
7 Cardiovascular, Respiratory & Endocrine Disease
6.1 Cardiovascular Disease 6.2 Respiratory Disease 6.3 Endocrine Disease & Diabetes 6.4 Bleeding Disorders & Anticoagulation
8 Haematology, Infection & the Medically Compromised Patient
7.1 Haematology 7.2 Infectious Disease 7.3 The Medically Compromised Patient 7.4 Neurological & Gastrointestinal Disease
9 Medical Emergencies in Dental Practice
8.1 Medical Emergencies & Resuscitation 8.2 Anaphylaxis & Acute Allergy 8.3 Emergency Drugs & the Resuscitation Kit
10 Special Care Dentistry, Mental Health & Anxiety Management
9.1 Special Care Dentistry & Patients with Disability 9.2 Mental Health & Behavioural Science 9.3 Dental Anxiety & Behaviour Management
11 Oral Medicine — Mucosal Disease & Orofacial Pain
10.1 Oral Mucosal Disease & Lichen Planus 10.2 Vesiculobullous & Ulcerative Disorders 10.3 Candidiasis & Fungal Infections 10.4 Orofacial Pain & Neuropathic Disorders
12 Oral Pathology — Lesions, Cysts, Tumours & Salivary Glands
11.1 Premalignant Lesions & Oral Cancer 11.2 Odontogenic Cysts 11.3 Odontogenic & Non-Odontogenic Tumours 11.4 Salivary Gland Disease
13 Pharmacology — Local Anaesthesia, Analgesia & Sedation
12.1 Local Anaesthesia 12.2 Analgesics & NSAIDs 12.3 Conscious Sedation
14 Pharmacology — Antimicrobials, Prescribing & Drug Interactions
13.1 Antimicrobials & Antibiotic Stewardship 13.2 Prescribing & Drug Interactions
15 Dental Materials
14.1 Properties & Testing of Dental Materials 14.2 Amalgam & Metal Restorations 14.3 Composite Resin & Adhesive Dentistry 14.4 Impression Materials, Cements & Other Materials
16 Microbiology, Infection Control & Radiology
15.1 Oral Microbiology & Infection Control 15.2 Dental Radiology & Imaging 15.3 Radiation Protection
17 Law, Ethics, Professionalism & Evidence-Based Dentistry
16.1 Consent & Confidentiality 16.2 GDC Standards & Professionalism 16.3 Safeguarding & Duty of Candour 16.4 Evidence-Based Dentistry & Research Methods 16.5 Records, Information Governance & Regulation 16.6 Communication, Teamworking, Human Factors & Raising Concerns
18 Statistics, Dental Public Health, Critical Appraisal & Exam Strategy
17.1 Statistics & Critical Appraisal 17.2 Dental Public Health & Epidemiology 17.3 SBA Technique & Exam Strategy 17.4 Final Review & Key Points
6.4 Bleeding Disorders & Anticoagulation
Key Takeaways Explain This Topic AI
SDCEP (2nd edition, 2022) recommends treating patients on warfarin without interrupting therapy if INR is below 4.0, with INR checked ideally within 24 hours of surgery
For higher-bleeding-risk dental procedures on a DOAC, SDCEP advises omitting the morning dose (apixaban/dabigatran) or delaying the morning dose (rivaroxaban/edoxaban), with the next dose no earlier than 4 hours after haemostasis
Aspirin and clopidogrel should generally not be stopped for dental treatment; interrupting antiplatelet therapy in patients with stents risks stent thrombosis and MI
Local haemostatic measures — sutures, oxidised cellulose (Surgicel), and tranexamic acid 4.8% mouthwash for 2 days — are first-line for managing postoperative bleeding
Severe inherited bleeding disorders (haemophilia, von Willebrand disease) require haematology liaison and individualised factor replacement plans before surgery
Last updated: August 2026
Inherited Bleeding Disorders
Disorder Defect Inheritance Dental relevance
Haemophilia A Factor VIII deficiency X-linked recessive Spontaneous bleeding, haemarthroses; need factor replacement for surgery
Haemophilia B Factor IX deficiency X-linked recessive Same pattern as haemophilia A; replacement with factor IX
von Willebrand disease (vWD) von Willebrand factor deficiency or dysfunction Usually autosomal dominant Mucosal bleeding common; desmopressin (DDAVP) may help type 1
Dental management
Consult haematology before any invasive procedure. A written plan covering factor replacement, timing, and postoperative monitoring is essential.
Avoid intramuscular injections and inferior alveolar nerve blocks where possible in severe disease (risk of compartment bleeding).
Use local haemostatic measures (sutures, oxidised cellulose/Surgicel, tranexamic acid mouthwash).
For children or severe cases, treatment may be in a specialist centre.
Acquired Bleeding Disorders
Thrombocytopenia (platelet count < 150 x 10^9/L) may be immune (ITP), drug-related, or secondary to leukaemia or marrow failure. Bleeding risk rises sharply below 50 x 10^9/L; check with haematology before surgery and consider platelet transfusion for counts < 30–50 x 10^9/L before invasive dental work.
Leukaemia and other haematological malignancies cause thrombocytopenia, neutropenia, and impaired clotting; liaise with the oncology/haematology team and time dental work around chemotherapy cycles.
Liver disease impairs synthesis of vitamin K-dependent factors; check coagulation and platelets before surgery.
- Anticoagulants
- Warfarin (vitamin K antagonist)
Warfarin inhibits vitamin K-dependent clotting factors (II, VII, IX, X). It is monitored by the international normalised ratio (INR) . Target INR varies by indication:
AF, DVT/PE : typically 2.0–3.0.
Mechanical mitral valve : typically 2.5–3.5 (higher for some valves).
SDCEP warfarin guidance (2nd edition, 2022)
Treat without interrupting warfarin if INR < 4.0 (strong recommendation).
Check INR ideally within 24 hours of surgery (up to 72 hours acceptable if the patient is stably anticoagulated).
If INR >= 4.0 , contact the anticoagulation service or GP and delay invasive treatment until INR is below 4.0; for urgent treatment, refer to secondary care.
A 'stable' patient is one who does not require weekly monitoring and has had no INR > 4 in the last two months.
Direct oral anticoagulants (DOACs)
DOACs (also called NOACs) directly inhibit thrombin or factor Xa:
- Drug Target Dosing
- Apixaban Factor Xa Twice daily
- Rivaroxaban Factor Xa Once daily
- Dabigatran Thrombin (IIa) Twice daily
- Edoxaban Factor Xa Once daily
- SDCEP DOAC guidance
Bleeding risk is categorised as low (e.g. 1–3 simple extractions, restorations with subgingival margins) or higher (e.g. >3 extractions, complex or surgical extractions, flap raising, implants, biopsies).
Low-risk procedures: treat without interrupting the DOAC.
Higher-risk procedures:
Apixaban or dabigatran (twice daily): omit the morning dose on the day of treatment; the evening dose can be taken as usual, but no earlier than 4 hours after haemostasis .
Rivaroxaban or edoxaban (once daily, morning): delay the morning dose ; it may be taken 4 hours after haemostasis , with the next dose as usual the following morning.
Rivaroxaban or edoxaban (once daily, evening): no dose modification needed.
Antiplatelet Drugs
Aspirin (cyclooxygenase inhibitor) and clopidogrel (P2Y12 ADP-receptor antagonist) are commonly used alone or in combination (dual antiplatelet therapy, DAPT) after coronary stenting or acute coronary syndromes.
Do not stop antiplatelet therapy for routine dental treatment, including simple extractions. Interruption of DAPT in a patient with a recent stent risks stent thrombosis and myocardial infarction .
Local haemostatic measures are usually sufficient.
For complex surgery or multiple extractions, plan with the cardiology or haematology team.
Local Haemostatic Measures
All patients at increased bleeding risk should have local measures planned in advance:
Sutures — close the socket to approximate wound edges.
Oxidised cellulose (Surgicel) — a resorbable haemostatic dressing packed into the socket.
Tranexamic acid 4.8% mouthwash — 10 mL rinsed for 5 minutes, four times daily for 2 days; do not eat or drink for 1 hour after each rinse.
Pack the socket with gelatin sponge (e.g. Gel foam) if needed.
Avoid NSAIDs for postoperative analgesia; use paracetamol.
Practical Treatment Plan
- Patient group Pre-operative check Procedure
- Warfarin, stable INR within 24–72 h, must be < 4.0 Proceed without interrupting warfarin
- Warfarin, INR >= 4.0 Contact anticoagulation service Delay until INR < 4.0; urgent care in secondary care
- DOAC, low-risk procedure No dose change Proceed without interrupting
DOAC, higher-risk procedure Plan dose omission per SDCEP Omit/delay morning dose; resume >= 4 h after haemostasis
- Aspirin or clopidogrel None Proceed; do not stop antiplatelet
- Severe haemophilia / vWD Haematology plan with factor cover Specialist centre where indicated
- General measures
Plan treatment early in the day and early in the week so bleeding can be reviewed and help is available.
Limit the initial treatment area (e.g. single extraction, then assess bleeding before proceeding).
Consider staging extensive procedures over separate visits.
Only discharge the patient once haemostasis has been achieved .
Give clear written postoperative advice and a contact number for bleeding problems.